Clinical Trial Update: Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of atezolizumab with bevacizumab in previously untreated metastatic/unresectable urothelial carcinoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Arjun Balar, MD | Conditions: Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-01-07